GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - GT Biopharma, Inc. (GTBP) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2026, GT Biopharma is expected to earn -$0.32 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 54.3% over the past three months, reflecting a positive trend in earnings outlook [8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade of GT Biopharma to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].